Latest & greatest articles for migraine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on migraine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on migraine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for migraine

121. Injection of Botulinum Toxin (Botox) for Prophylaxis of Headaches in Adults with Chronic Migraine

Injection of Botulinum Toxin (Botox) for Prophylaxis of Headaches in Adults with Chronic Migraine 1/5 Public Summary Document Application No. 1168 – Botulinum toxin type A for the prophylaxis of headaches in patients with chronic migraine Sponsor/Applicant/s: Allergan Australia Pty Ltd Date of MSAC consideration: 1 August 2013 1. Purpose of application In February 2011, an application to the Medical Services Advisory Committee (MSAC) was received from Allergan Australia Pty Ltd for injection (...) of botulinum toxin type A (BOTOX ® ) for the prevention (prophylaxis) of chronic migraine. The MSAC application was co-dependent on an application to the Pharmaceutical Benefits Advisory Committee (PBAC) for the drug component of the service (i.e. extension of the current Botulinum Toxin Program (Section 100 arrangements) so the drug is listed for prophylaxis of headaches in adults with chronic migraine who meet certain criteria). The application was lodged during transitional arrangements for managing co

Medical Services Advisory Committee2013

122. Structural brain changes in migraine.

Structural brain changes in migraine. CONTEXT: A previous cross-sectional study showed an association of migraine with a higher prevalence of magnetic resonance imaging (MRI)-measured ischemic lesions in the brain. OBJECTIVE: To determine whether women or men with migraine (with and without aura) have a higher incidence of brain lesions 9 years after initial MRI, whether migraine frequency was associated with progression of brain lesions, and whether progression of brain lesions was associated (...) with cognitive decline. DESIGN, SETTING, AND PARTICIPANTS: In a follow-up of the 2000 Cerebral Abnormalities in Migraine, an Epidemiological Risk Analysis cohort, a prospective population-based observational study of Dutch participants with migraine and an age- and sex-matched control group, 203 of the 295 baseline participants in the migraine group and 83 of 140 in the control group underwent MRI scan in 2009 to identify progression of MRI-measured brain lesions. Comparisons were adjusted for age, sex

JAMA2012 Full Text: Link to full Text with Trip Pro

123. A Randomized Controlled Trial of a Comprehensive Migraine Intervention Prior to Discharge From an Emergency Department

A Randomized Controlled Trial of a Comprehensive Migraine Intervention Prior to Discharge From an Emergency Department 22994458 2012 10 16 2013 04 10 2016 12 15 1553-2712 19 10 2012 Oct Academic emergency medicine : official journal of the Society for Academic Emergency Medicine Acad Emerg Med A randomized controlled trial of a comprehensive migraine intervention prior to discharge from an emergency department. 1151-7 10.1111/j.1553-2712.2012.01458.x Patients who use an emergency department (ED (...) ) for acute migraine headaches have higher migraine disability scores, lower socioeconomic status, and are unlikely to have used a migraine-specific medication prior to presentation to the ED. The objective was to determine if a comprehensive migraine intervention, delivered just prior to ED discharge, could improve migraine impact scores 1 month after the ED visit. This was a randomized controlled trial of a comprehensive migraine intervention versus typical care among patients who presented to an ED

EvidenceUpdates2012 Full Text: Link to full Text with Trip Pro

124. Triptans for migraine headaches: a review of clinical evidence on safety

Triptans for migraine headaches: a review of clinical evidence on safety Triptans for migraine headaches: a review of clinical evidence on safety Triptans for migraine headaches: a review of clinical evidence on safety CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Triptans for migraine headaches: a review of clinical (...) 10 mg/month did not reduce the number of migraine days compared with providing a formulary limit of 9 tablets per month. Regardless of quantity, rizatriptan ODT 10 mg was well tolerated as AEs were similar between groups. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Analgesics; Migraine Disorders; Tryptaminess Language Published English Country of organisation Canada Province or state Ontario English summary An English language summary is available. Address

Health Technology Assessment (HTA) Database.2012

125. Genesis? implantable pulse generator for chronic migraine

Genesis? implantable pulse generator for chronic migraine Genesis™ implantable pulse generator for chronic migraine Genesis™ implantable pulse generator for chronic migraine NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Genesis™ implantable pulse generator for chronic migraine. Birmingham: NIHR Horizon Scanning Centre (...) (NIHR HSC). Horizon Scanning Review. 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Defibrillators, Implantable; Migraine Disorderss; Pacemaker, Artificial; Prostheses and Implants Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences

Health Technology Assessment (HTA) Database.2012

126. Occipital nerve stimulation for chronic cluster headache and chronic migraine headache

Occipital nerve stimulation for chronic cluster headache and chronic migraine headache Occipital nerve stimulation for chronic cluster headache and chronic migraine headache Occipital nerve stimulation for chronic cluster headache and chronic migraine headache Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Occipital nerve stimulation for chronic cluster (...) headache and chronic migraine headache. Lansdale: HAYES, Inc.. Directory Publication. 2012 Authors' conclusions Occipital nerve stimulation (ONS) is a type of peripheral nerve stimulation that has been investigated as a way to treat medically refractory (intractable) headache disorders, including chronic cluster-type headache and migraine headache. The procedure involves the subcutaneous implantation of electrodes and consequent electrical stimulation of the suboccipital region of the scalp

Health Technology Assessment (HTA) Database.2012

127. Review: Prophylactic botulinum toxin A reduces frequency of chronic migraine headaches in adults.

Review: Prophylactic botulinum toxin A reduces frequency of chronic migraine headaches in adults. ACP Journal Club: review: prophylactic botulinum toxin A reduces frequency of chronic migraine headaches in adults. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography (...) Citation manager Format Create File 1 selected item: 22910964 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Aug 21;157(4):JC2-10. doi: 10.7326/0003-4819-157-4-201208210-02010. ACP Journal Club: review: prophylactic botulinum toxin A reduces frequency of chronic migraine headaches in adults. 1 , . 1 Kansas University School

Annals of Internal Medicine2012

128. Surgery for treatment of migraine headache

Surgery for treatment of migraine headache Surgery for treatment of migraine headache Surgery for treatment of migraine headache Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Surgery for treatment of migraine headache. Lansdale: HAYES, Inc.. Directory Publication. 2012 Authors' conclusions Surgical deactivation of migraine trigger sites is intended to treat (...) patients with refractory migraine headache disorder that cannot be managed by conventional treatments, and patients who are intolerant of the side effects of conventional treatments. The procedure involves the resection of one or more muscle groups that may be compressing specific nerves causing refractory migraine headache Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Migraine Disorderss; Neurosurgical Procedures Language Published

Health Technology Assessment (HTA) Database.2012

129. Botulinum toxin a for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis

Botulinum toxin a for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis Jackson JL, Kuriyama A, Hayashino Y CRD summary The authors concluded that botulinum toxin A compared to placebo may be associated with benefit for chronic daily headaches and (...) chronic migraines, but not episodic migraine or chronic tension headaches. Despite some issues with the included trials, which the authors acknowledged, this was a generally thorough analysis and the authors' conclusions seem reasonable and reflect the uncertainty surrounding the evidence. Authors' objectives To assess the effects of botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults. Searching MEDLINE, EMBASE and The Cochrane Library were searched between 1966

DARE.2012

130. Randomized Trial of Sumatriptan and Naproxen Sodium Combination in Adolescent Migraine

Randomized Trial of Sumatriptan and Naproxen Sodium Combination in Adolescent Migraine 22585767 2012 06 04 2012 08 07 2013 11 21 1098-4275 129 6 2012 Jun Pediatrics Pediatrics Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. e1411-20 10.1542/peds.2011-2455 Treatment of adolescent migraine remains a significant unmet medical need. We compared the efficacy and safety of 3 doses of sumatriptan and naproxen sodium (suma/nap) combination tablets to placebo (...) in the acute treatment of adolescent migraine. This randomized, parallel group study in 12 to 17 year olds required 2 to 8 migraines per month (typically lasting >3 hours untreated) for ≥ 6 months. Subjects entered a 12-week run-in phase, treating 1 moderate-to-severe migraine (attack 1) with single-blind placebo. Subjects reporting headache pain 2 hours after dosing were randomly assigned into a 12-week double-blind phase, treating 1 moderate-to-severe migraine (attack 2) with placebo (n = 145), suma/nap

EvidenceUpdates2012

132. Two Center, Randomized Pilot Study of Migraine Prophylaxis Comparing Paradigms Using Pre-Emptive Frovatriptan or Daily Topiramate: Research and Clinical Implications

Two Center, Randomized Pilot Study of Migraine Prophylaxis Comparing Paradigms Using Pre-Emptive Frovatriptan or Daily Topiramate: Research and Clinical Implications 22188311 2012 05 08 2013 05 10 2015 11 19 1526-4610 52 5 2012 May Headache Headache Two center, randomized pilot study of migraine prophylaxis comparing paradigms using pre-emptive frovatriptan or daily topiramate: research and clinical implications. 749-64 10.1111/j.1526-4610.2011.02054.x To compare the efficacy and clinical (...) benefit of 2 paradigms of migraine prevention using pre-emptive frovatriptan and daily topiramate. The study compares the paradigms of pre-emptive use of frovatriptan, a drug approved for acute migraine, and the daily use of topiramate, a Federal Drug Administration-approved and -accepted standard for migraine prophylaxis. Traditionally, preventive treatment of migraine required daily medication. However, recent studies suggest that pre-emptive prophylaxis may be beneficial to those migraineurs who

EvidenceUpdates2012

133. WITHDRAWN: Oral sumatriptan for acute migraine.

WITHDRAWN: Oral sumatriptan for acute migraine. BACKGROUND: Migraine is a common neurovascular disorder characterized by recurrent episodes of disabling headache, autonomic nervous system dysfunction, and, in some patients, neurological aura symptoms. Sumatriptan is one of a class of selective serotonin 5-hydroxytryptamine (5-HT1B/1D) agonists (triptans) thought to relieve migraine attacks by several mechanisms, including cranial vasoconstriction and peripheral and central neural inhibition (...) . OBJECTIVES: To describe and assess the evidence from randomized controlled trials (RCTs) concerning the efficacy and tolerability of oral sumatriptan for the treatment of a single acute attack of migraine in adults. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (Cochrane Library, Issue 4, 2001), MEDLINE (1966 through November 2001), and reference lists of articles and books. SELECTION CRITERIA: We included double-blind RCTs comparing oral sumatriptan (100 mg, 50 mg, 25 mg

Cochrane2012

135. Cost-effectiveness analysis of early versus non-early intervention in acute migraine based on evidence from the 'Act when Mild' study

Cost-effectiveness analysis of early versus non-early intervention in acute migraine based on evidence from the 'Act when Mild' study Cost-effectiveness analysis of early versus non-early intervention in acute migraine based on evidence from the 'Act when Mild' study Cost-effectiveness analysis of early versus non-early intervention in acute migraine based on evidence from the 'Act when Mild' study Slof J Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of early versus later treatment with almotriptan, for acute migraine. The author concluded that early treatment of acute migraine was cost saving from a French societal perspective, and likely to be cost-effective from

NHS Economic Evaluation Database.2012

136. Acute migraine treatment in emergency settings

Acute migraine treatment in emergency settings Acute migraine treatment in emergency settings Acute migraine treatment in emergency settings Sumamo Schellenberg E, Dryden DM, Pasichnyk D, Ha C, Vandermeer B, Friedman BW, Colman I, Rowe BH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Sumamo Schellenberg E, Dryden DM, Pasichnyk D, Ha C (...) , Vandermeer B, Friedman BW, Colman I, Rowe BH. Acute migraine treatment in emergency settings. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 84. 2012 Authors' objectives To compare the effectiveness and safety of parenteral pharmacological interventions to treat migraine headaches in adults presenting to the emergency department (ED). Authors' conclusions Many agents are effective in the treatment of acute migraine headache when compared with placebo

Health Technology Assessment (HTA) Database.2012

138. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine

Botulinum toxin type A for the prevention of headaches in adults with chronic migraine Botulinum toxin type A for the prevention of headaches in adults with chronic migraine | Guidance and guidelines | NICE Botulinum toxin type A for the prevention of headaches in adults with chronic migraine Technology appraisal guidance [TA260] Published date: 27 June 2012 Share Guidance wherever possible. Explore Guidance app Copyright © 2017 National Institute for Health and Care Excellence. All rights

National Institute for Health and Clinical Excellence - Technology Appraisals2012

139. Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison

Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison Asseburg C, Peura P, Oksanen T, Turunen J, Purmonen T, Martikainen J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary To objective was to assess cost-effectiveness of oral triptans therapy for acute migraine attacks in Finland. The authors concluded eletriptan 40mg was cost-effective beyond a willingness-to-pay for a sustained pain-free period with no adverse events of €44 (QALY €20,000). Sumatriptan was cost-effective below these thresholds. The analysis was generally well

NHS Economic Evaluation Database.2012

140. NSAIDs and other complementary treatments for episodic migraine prevention in adults

NSAIDs and other complementary treatments for episodic migraine prevention in adults Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: [RETIRED] | Neurology Advertisement Search for this keyword Main menu User menu Search Search for this keyword The most widely read and highly cited peer-reviewed neurology journal Share April 24, 2012 ; 78 (17) Special Articles Evidence-based guideline update: NSAIDs and other complementary (...) treatments for episodic migraine prevention in adults: [RETIRED] Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society S. Holland , S.D. Silberstein , F. Freitag , D.W. Dodick , C. Argoff and E. Ashman First published April 23, 2012, DOI: https://doi.org/10.1212/WNL.0b013e3182535d0c S. Holland From the Armstrong Atlantic State University (S.H.), Savannah, GA; Thomas Jefferson University (S.D.S.), Jefferson Headache Center, Philadelphia, PA

American Academy of Neurology2012